During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Michael Wang, MD Anderson Cancer Center, Houston, US, discussing current therapies for MCL and their combinations.
Wang provided an overview of current therapies for MCL, highlighted key clinical data, and offered insights into their clinical application. He also discussed novel therapies and combinations, and potential future directions.
This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.
